Published in TB and Outbreaks Week, October 23rd, 2001
Heska anticipates a positive reception for the product, given the vaccine's success in the U.S. After 20 months of field experience, the Flu Avert I.N. has proved safe and effective, according to the company. The product is gaining momentum in the U.S. marketplace, with current-year sales up approximately 70% over the prior year.
"The registration of the Flu...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.